BridgeBio Pharma, Inc. (2CL)
XFRA 
Summary
2CL Chart
Biotech Stock Could Turn 4-Year Peak Into Records
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
BridgeBio Pharma, Inc. ( BBIO ) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wade Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma.
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. ( BBIO ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer Thomas Trimarchi - CFO & President Conference Call Participants Salim Syed - Mizuho Securities USA LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Lin Tsai - Jefferies LLC, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Jason Zemansky - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Trevor Allred - Oppenheimer & Co. Inc., Research Division Presentation Operator Good afternoon. I will be your conference operator today.
BridgeBio Pharma, Inc. (2CL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has BridgeBio Pharma, Inc. ever had a stock split?
BridgeBio Pharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Neil Kumar CEO | XFRA Exchange | US10806X1028 ISIN |
| US Country | 725 Employees | - Last Dividend | - Last Split | 27 Jun 2019 IPO Date |
Overview
BridgeBio Pharma, Inc. stands as a prominent figure in the commercial-stage biopharmaceutical sector, dedicated to developing groundbreaking medicines aimed at treating genetic diseases and cancers. Since its inception in 2015, the company has been at the forefront of medical research, leveraging advanced scientific methods to discover, create, test, and deliver transformative treatments. Operating out of Palo Alto, California, BridgeBio Pharma is fuelled by collaborations and license agreements with esteemed institutions such as the Leland Stanford Junior University and Leidos Biomedical Research, Inc. Through its relentless pursuit of medical innovation, BridgeBio Pharma strives to offer new hope to patients facing some of the most challenging medical conditions.
Products and Services
- AG10
This compound is a next-generation oral small molecule designed to be a near-complete TTR stabilizer. Currently in Phase 3 clinical trials, AG10 targets the treatment of TTR amyloidosis or transthyretin amyloid cardiomyopathy (ATTR-CM), a significant advancement in addressing this condition.
- Low-dose Infigratinib
An oral FGFR1-3 selective tyrosine kinase inhibitor, low-dose infigratinib is under a Phase 3 double-blinded, placebo-controlled pivotal study. It represents a potential treatment option for children with achondroplasia, showcasing BridgeBio Pharma’s commitment to addressing rare genetic growth disorders.
- BBP-631
BridgeBio Pharma is advancing BBP-631, an AAV5 gene transfer product candidate, through a Phase 1/2 clinical trial. This innovative therapy targets congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD), offering a novel gene therapy approach to this adrenal disorder.
- Encaleret
A small molecule antagonist of the calcium sensing receptor (CaSR), Encaleret is currently in a phase 3 clinical trial. This product aims to treat autosomal dominant hypocalcemia type 1 (ADH1), underscoring the company's focus on developing treatments for rare metabolic disorders.
- BBP-418
In Phase 3 clinical trial, BBP-418 is a glycosylation substrate pro-drug for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This highlights BridgeBio Pharma’s commitment to combating muscular dystrophies through cutting-edge therapies.
